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Under the auspice of the Clinical Practice Guideline Quality Indicator Committee of the European Society of
Cardiology (ESC), the Working Group for cardiac pacing QIs was formed. The Group comprised Task Force mem-
bers of the 2021 ESC Clinical Practice Guidelines on Cardiac Pacing and Cardiac Resynchronization Therapy, mem-
bers of the European Heart Rhythm Association, international cardiac device experts, and patient representatives.
We followed the ESC methodology for QI development, which involved (i) the identification of the key domains
of care by constructing a conceptual framework of the management of patients receiving cardiac pacing, (ii) the de-
velopment of candidate QIs by conducting a systematic review of the literature, (iii) the selection of the final set of
QIs using a modified-Delphi method, and (iv) the evaluation of the feasibility of the developed QIs. Four domains
of care were identified: (i) structural framework, (ii) patient assessment, (iii) pacing strategy, and (iv) clinical out-
comes. In total, seven main and four secondary QIs were selected across these domains and were embedded
within the 2021 ESC Guidelines on Cardiac Pacing and Cardiac Resynchronization therapy.
...................................................................................................................................................................................................
Conclusion By way of a standardized process, 11 QIs for cardiac pacing were developed. These indicators may be used to
quantify adherence to guideline-recommended clinical practice and have the potential to improve the care and out-
comes of patients receiving cardiac pacemakers.
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Introduction
Cardiac pacing is frequently used to reduce morbidity and mortality
in patients with cardiac rhythm disturbances.1 Expanding pacing indi-
cations, an ageing population and an increased life expectancy have
led to increasing pacemaker implantation rates in recent years.2,3
Even so, large variations in the rates of implantation and associated
complications has been observed within and between countries.3,4
According to the European Society of Cardiology (ESC)
Cardiovascular Disease Statistics, in 2018/19 age- and sex-
standardized implantation rates ranged from <60 to >1000 pace-
makers per million people across ESC member countries.5 Clinical
registries provide an opportunity to capture real-world naturalistic
data on cardiac pacing to better understand variations and gaps in
practice.4,6 However, there is a need to develop and standardize the
tools by which the quality of care for cardiac pacing is evaluated and
resultant outcomes monitored and reported. Such tools may inte-
grate with, and provide, the means to develop clinical registries for
cardiac pacing, as well as have the potential to improve patient
outcomes.
Quality indicators (QIs) are increasingly used to measure the qual-
ity of medical care. They provide an opportunity to quantify geo-
graphic variation, and identify areas where quality improvement
interventions are needed.7 QIs may serve as a means of closing the
second translational gap between evidence and practice and facilitate
a unified approach to the appraisal of care using clinical registries.8
While a few individual indicators for cardiac devices have been devel-
oped by the Centres for Medicare and Medicaid Services,9–11 we are
not aware of any published set of QIs for cardiac pacing. This is in
contrast to sets of QIs by the ESC,12,13 and other professional socie-
ties.14,15 Therefore, the ESC established the Working Group for car-
diac pacing QIs to work on the development of indicators of care
quality for cardiac pacing in collaboration with the European Heart
Rhythm Association (EHRA) and in parallel with the writing of the
2021 ESC Guidelines on Cardiac Pacing and Cardiac
Resynchronization Therapy. This was undertaken under the auspice
of the Clinical Practice Guideline Quality Indicator Committee of the
ESC. This article describes the process by which the ESC QIs for car-
diac pacing were developed and provide their measurement
specifications.
Methods
The methodology by which the ESC develops QIs for the quantification
of cardiovascular care and outcomes has been published.16 In brief, the
methodology involves (i) the identification of key domains of care by con-
structing a conceptual framework of the patients’ management, (ii) the
development of candidate QIs by conducting a systematic review of the
literature, (iii) the selection of the final set of QIs using a modified-Delphi
method, and (iv) the evaluation of the feasibility of the developed QIs.16
The term QI is used here to describe a discreet clinical situation in which
a process of care is, or is not, recommended to allow specific measure-
ments of performance. QIs can relate to the structure, process or out-
comes of care, and include main and secondary indicators. The main
indicators are those that have higher validity and feasibility by the
Working Group members and thus may be used for measurement across
regions and over time. Both the main and secondary QIs may be used for
local quality improvement activities.16
Members of the Working Group
The Working Group comprised members of the Task Force of the 2021
ESC Guidelines on Cardiac Pacing and Cardiac Resynchronization
Therapy, members of the ESC Quality Indicator Committee, nominees
from EHRA and the ESC Patient Forum, as well as international experts
in cardiac devices. In total, 25 members from 13 countries participated in
the Working Group, and attended a series of virtual meetings between
November 2020 and March 2021.














The Working Group defined the ‘target population’ for the developed
QIs as patients for whom a decision has been made to implant a cardiac
pacemaker for bradyarrhythmia indication in accordance with the 2021
ESC Guidelines on Cardiac Pacing and Cardiac Resynchronization
Therapy.1 As such, patients with an indication for an implantable defibril-
lator and those undergoing device therapy for heart failure have been ex-
cluded. In addition, the definition used for the ‘target population’
excluded patients with undiagnosed bradyarrhythmia—thereby simplify-
ing the operationalization of quality assessment when the QIs are
established.
The Working Group defined, for each process QI, a denominator
which describes the patient group eligible for the measurement, a numer-
ator which outlines the criteria by which the QI is accomplished, a mea-
surement period which specifies the time point at which the quality
assessment is taking place, and a measurement duration which is the time
frame needed for enough cases to be collected in order to accumulate
meaningful data. For structural QIs, only numerator definitions were pro-
vided because these are binary (yes, no) measurements.12
Literature review
During the initial phases of the development process, the Working
Group agreed on the specifications for the literature review and on the
key domains of cardiac pacing care. These domains were identified by
constructing a conceptual illustration of the care provision pathway,
which formed the framework for the development of the QIs (Figure 1).16
In addition, there was an agreement between the Working Group mem-
bers on patient-related outcome measures as an important domain of
care for cardiac pacing. As such, patient-reported outcome measures,
including the assessment of health-related quality of life using various
tools were obtained from the literature.
We conducted a literature search of articles pertinent to cardiac pac-
ing including publications from clinical registries,3,17 international guide-
lines,18,19 as well as the Centres for Medicare and Medicaid Services
indicators,9–11 and societal recommendations.20 The literature review
aimed to identify structural components or processes of cardiac pacing
care that have a strong association with favourable patients’ outcomes,
while the goal of the Clinical Practice Guidelines review was to assess the
suitability of the class I and class III recommendations against the ESC cri-
teria for QIs (Supplementary material online, Table S1).
Furthermore, and to help identify the optimal pacing strategy for
patients requiring a de novo permanent pacemaker for bradyarrhythmia,
a systematic review and a meta-analysis were conducted simultaneously
with the development of this document.21 This review highlighted that
whilst novel pacing modalities such as His-bundle pacing and left bundle
branch area pacing maintain physiological ventricular activation, the pub-
lished studies to date are limited by their observational design or sample
size and that comparative studies are needed to understand the impact of
such pacing strategies on clinical outcomes.21
Consensus development
Modified Delphi process
The candidate QIs derived from the aforementioned process were evalu-
ated using the modified Delphi method.16 The ESC criteria for QI devel-
opment (Supplementary material online, Table S1) were shared with the
Working Group members prior to the voting in order to standardize the
selection process. All candidate QIs were graded for validity and feasibility
by each panellist via an online questionnaire using a 9-point ordinal
Figure 1 Conceptual framework of cardiac pacing patient journey.
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scale.16 Two rounds in total were conducted, with teleconferences in be-
tween to discuss the results of the vote and address any concerns or
ambiguities.
Analysing voting results
A 9-point ordinal scale was used in the Delphi rounds. Ratings of 1 to 3
were interpreted as the QI was not valid/feasible, with ratings of 4 to 6
meaning that the QI was of an uncertain validity/feasibility and ratings of 7
to 9 that the QI was valid/feasible. For each candidate QI, the median and
the mean deviation from the median were calculated to provide the cen-
tral tendency and the dispersion of votes. Cut-offs for inclusion were sim-
ilar to those reported in the literature.22 Thus, candidate QIs with median
scores >_7 for validity, >_4 for feasibility, and with minimal inter-rater varia-
tion were included in the final set of QIs. We defined those QIs fulfilling
the above numerical threshold for inclusion following the first voting
round as the main QIs, while those fulfilling the numerical threshold for




Four domains of cardiac pacing care were identified by the Working
Group. These included: (i) structural framework domain, which eval-
uates the characteristics of the centres providing a cardiac pacing ser-
vice, (ii) patient assessment domain, which evaluates the
appropriateness of the investigations performed prior to cardiac pac-
ing implantation, (iii) pacing strategy domain, which evaluates the se-
lection of the pacing method, and (iv) outcomes domain, which
captures the clinical outcomes of cardiac pacing (Figure 2).
Quality indicators
The literature search retrieved a total of 25 candidate QIs, which
were included in the first round of the voting process. Of those and
based on the parameters above, 12 (48%) were excluded and 7
(28%) were included as main QIs. The remaining 6 QIs were deemed
inconclusive and were, therefore, carried to a second voting round,
following which 4 (67%) were included as secondary QIs. Of the 11
selected QIs, 5 (46%) related to the structural framework domain, 3
(27%) to the patient assessment domain, 1 (9%) to the pacing strat-
egy domain, and 2 (18%) to the outcome domain (Figure 2).
According to the voting results, the proposed patient-reported out-
come measures did not meet the inclusion criteria and so none were
selected for the final set of indicators.
Domain 1: Structural framework
Structural QIs evaluate the characteristics of the centres providing
cardiac pacing service, and play a role in quality assessment at the in-
stitutional level. The association between certain aspects of cardiac
devices patient care and outcomes has been facilitated by well-
conducted registries at the national level.4 As such, the participation
in at least one registry for cardiac pacing is an indicator of care quality
(Main 1.1). In addition, data from observational studies have shown
an inverse association between the centre procedural volume and
complication rates and thus the monitoring and reporting of the
centre-specific annual rate of cardiac pacing implantation is recom-
mended (Main 1.2) (Table 1).4,23
The other three indicators in the structural domain include the
availability of resources for the risk-stratification and clinical charac-
terization of patients undergoing cardiac pacing, such as ambulatory
rhythm monitoring and echocardiography (Main 1.3),20 of follow-up
protocols within 2–12 weeks after device implantation (Main 1.4),
and the presence of pre-procedural checklists documenting a discus-
sion with patients regarding the risks and benefits of device implanta-
tion and alternative treatment options prior to implantation (Main
1.5) (Table 1).
Domain 2: Patient assessment
Patient evaluation and preparation prior to cardiac pacing implanta-
tion reduces the risks of complications associated with the procedure
and guides the selection of an appropriate pacing strategy.24,25
Evidence favours the efficacy of prophylactic antibiotics in reducing
the rates of cardiac device-related infections (Main 2).26,27 The per-
formance of basic blood tests, such as full blood count and coagula-
tion profile may help identify patients with high risk of periprocedural
complications (Secondary 2.1),25 while the evaluation of the left ven-
tricular structure and function prior to cardiac pacing helps deter-
mine the most appropriate device for the patient (Secondary 2.2)
(Table 1).24
Domain 3: Pacing strategy
For patients with heart failure with a reduced ejection fraction who
have an indication for ventricular pacing and a high degree atrioven-
tricular block, biventricular pacing with cardiac synchronization ther-
apy has been shown to improve clinical outcomes over right
ventricular pacing. Thus, the proportion of patients who receive car-
diac synchronization therapy among those eligible was selected as a
QI (Secondary 3) (Table 1).24
Domain 4: Outcomes
The measurement of outcomes following cardiac pacing helps bench-
mark performance, monitor temporal trends of adverse events and
study the efficacy of quality improvement interventions. As such,
complications occurring within 30 days following device implantation
is delegated an indicator of care quality (Main 4). However, infections
related to cardiac pacing may be delayed beyond the first month fol-
lowing implantation.6 Accordingly, infections up to 1 year after device
insertion is also regarded as a measure of care quality (Secondary 4)
(Table 1).
Patient perspective
Patient-reported outcome measures reflect the patients’ perspective
of the impact of the condition and its treatment on their lives and are
important determinants of the patients’ perceived quality and out-
comes of care. Among the different categories of patient-reported
outcome measures, patients’ health-related quality of life is of interest
because it is multi-dimensional and allows the exploration of patients’
physical, emotional, and social well-being.28 While disease-specific
tools exist for a number of cardiovascular disease conditions, includ-
ing atrial fibrillation, arrhythmia, and heart failure, these capture lim-
ited data specific to cardiac devices implantation.29 As such, the
Delphi voting reached no consensus as to the inclusion of patient-
reported outcome measures in the final set of QIs with reason being
lack of specificity and limited evidence to support their use.
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Whereas there are common outcomes that matter to the majority
of patients, individual patients may have specific outcomes of a higher
importance to them based on a number of factors, such as their age
or sex. For instance, a physically active patient might be concerned
about restrictions of their arm and shoulder movement which may
affect the ability to perform certain activities. The appearance of the
scar and/or the implanted device may be more of a worry for women
than men, and elderly patients might have concerns about complica-
tions related to device implantation and therapies. As such, attention
is needed when designing patient-reported outcome measures to
capture not only what matters to the ‘average’ patient but also to in-
dividual patient’s values.
Furthermore, it should be noted that patients’ perceptions, par-
ticularly in cardiac pacing, may change over time. For example, the
implanted device implications on patients’ lives may differ accord-
ing to changes in their overall health, underlying condition, and re-
sponse to treatment.30 Therefore, the patient representatives
within the Working Group felt that it was important to capture
the trajectories of patients’ health-related quality of life following
cardiac device implantation, and proposed a non-exhaustive list of
potential areas for pacing QIs based on personal experience and
exchanges with other patients (Supplementary material online,
Table S2).
Discussion
In this document, we provide a suite of seven main and four second-
ary QIs that transcend four patient journey domains and may be used
in the evaluation of cardiac pacing care and outcomes. The QIs were
developed though a standardized methodology,16 which has been
used for the development of feasible and valid QIs for other cardio-
vascular conditions,12 and as a joint effort between the Task Force of
the 2021 ESC Guidelines on Cardiac Pacing and Cardiac
Resynchronization Therapy, EHRA, the ESC Patient Forum, and in-
ternational experts in cardiac devices under the remit of the ESC
Clinical Practice Guideline Quality Indicator Committee. The partici-
pation of stakeholders from 13 countries, including patients, and the
co-development of these QIs with the 2021 ESC Guidelines on
Cardiac Pacing and Cardiac Resynchronization Therapy, have
Figure 2 Domains of cardiac pacing care, with the corresponding QIs for each domain. Abx, antibiotics; AVB, atrioventricular block; CRT, cardiac
resynchronization therapy; ECG, electrocardiogram; EHRA, European Heart Rhythm Association; ESC, European Society of Cardiology; FBC, full
blood count; F/U, follow-up; HFrEF, heart failure with reduced ejection fraction; LVSF, left ventricle systolic function; TTE, transthoracic
echocardiography.
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enabled the provision of specific, measurable, and relevant QIs for
cardiac pacing care.
The growing number of cardiac pacemaker implantations across
Europe, and the variation in practice observed in clinical registries,
has created the necessity to develop standardized indicators for car-
diac pacing quality of care and outcomes. Although the Centres for
Medicare and Medicaid Services have developed individual measures
for cardiac devices, these are limited to specific domains of patients
care, such as follow-up following implantation,10 infection rates,9 and
complications after defibrillator implantation.11 Here, we propose a
suite of QIs that provides a framework that encompasses a wide and
comprehensive perspective of cardiac pacing care, including struc-
tural, process and outcome measures.
It is hoped that by providing QIs for cardiac pacing that are en-
dorsed by professional societies and co-developed with patients, a
systematic and international approach to the assessment of care and
Table 1 The 2021 ESC QIs for patients undergoing cardiac pacemaker implantation
Domain 1. Structural framework
Main (1.1): Centres providing CIED service should participate in at least one CIEDa registry.b
Numerator: Number of centres participating in at least one CIED registry.
Main (1.2): Centres providing CIED service should monitor and report the volume of procedures performed by individual operators on annual basis.b
Numerator: Number of centres monitoring and reporting the volume of procedures performed by individual operators.
Main (1.3): Centres providing CIED service should have available resources (ambulatory ECG monitoring, echocardiogram) to stratify patients according
to their risk for ventricular arrhythmias.b
Numerator: Number of centres with an available ambulatory ECG and echocardiogram service.
Main (1.4): Centres providing CIED service should have established protocols to follow-up patients within 2–12 weeks following implantation.b
Numerator: Number of centres that have an established protocols to follow-up patients within 2–12 weeks following CIED implantation.
Main (1.5): Centres providing CIED service should have a pre-procedural checklist to ensure discussion with patient regarding risks, benefits, and alterna-
tive treatment options.b
Numerator: Number of centres that have a checklist to ensure discussion with patient regarding risks, benefits, and alternative treatment options prior to
CIED implantation.
Domain 2. Patient assessment
Main (2): Proportion of patients considered for CIED implantation who receive prophylactic antibiotics 1 h before their procedure.c
Numerator: Number of patients who receive antibiotics 1 h before their CIED implantation.
Denominator: Number of patients who have CIED implantation.
Secondary (2.1): Proportion of patients considered for CIED implantation who have their full blood count and coagulation profile checked prior to the
procedure.c
Numerator: Number of patients who have their full blood count and coagulation profile checked prior to CIED implantation.
Denominator: Number of patients who have CIED implantation.
Secondary (2.2): Proportion of patients considered for CIED implantation who have an imaging evaluation of their LV structure and systolic function prior
to the procedure.c
Numerator: Number of patients who have an imaging evaluation of their LV structure and systolic function prior to CIED implantation.
Denominator: Number of patients who have CIED implantation.
Domain 3. Pacing strategy
Secondary (3): Proportion of patients with an indication for ventricular pacing and high degree AV block who have HFrEF and undergo CRT.c
Numerator: Number of patients with an indication for ventricular pacing and high degree AV block who have HFrEF and undergo CRT implantation.
Denominator: Number of patients with an indication for ventricular pacing and high degree AV block who have HFrEF and undergo CIED implantation.
Domain 4. Outcomes
Main (4): Annual rate of procedural complications 30 days following CIED implantation.d
Numerator: Number of patients who develop one or more of the procedural complicationse within 30 days from their CIED implantations
Denominator: Number of patients who have CIED implantation.
Secondary (4): Annual rates of CIED-related infections up to 1 year following CIED implantation, replacement, or revision.d
Numerator: Number of patients who develop CIED-related infections up to 1 year following CIED implantation, replacement, or revision.
Denominator: Number of patients who have CIED implantation, replacement, or revision.
AV, atrioventricular; CIED, cardiovascular implantable electronic device; CRT, cardiac resynchronization therapy; LV, left ventricular; QIs, quality indicators.
aCIED here refer to cardiac pacemakers.
bStructural QIs are binary measurements (Yes/No), and, thus, only numerator is defined.
cMeasurement period: encounter, measurement duration: annually.
dAnnual measurements.
eProcedural complications are defined as CIED-related bleeding, pneumothorax, cardiac perforation, tamponade, pocket haematoma, lead displacement (all requiring interven-
tion), or infection.










ercio user on 01 D
ecem
ber 2021
outcomes for patients undergoing cardiac pacemakers may be estab-
lished. Such a system may be used by the professional societies,
healthcare authorities or hospitals to identify and address unwanted
variation and monitor patterns of care. Consequently, policies and
quality improvement activities may be developed to facilitate continu-
ous benchmarking of performance over time and across regions, and
the subsequent behaviour change needed to improve care delivery.
The set of QIs that were developed may provide the basis for apply-
ing the process of Health Technology Assessment to the setting of
cardiac pacing.31
The four domains of cardiac pacing care for which the QIs were
developed cover broad spectrum of patient journey and may pro-
vide meaningful interpretation of care quality. We did not include
QIs relevant to procedural technique, such as venous access and
pacing site, in this document because these aspects of cardiac pac-
ing care are covered in a recent EHRA consensus document on
optimal implantation technique for pacemaker and implantable
cardioverter-defibrillator.32 In addition, QIs pertinent to novel
pacing modalities such as His-bundle pacing and left bundle branch
area pacing have not been selected by the Working Group mem-
bers. This may be explained by the limitations of the existing evi-
dence supporting such modalities.21
Furthermore, the Working Group acknowledges that other
domains may also be as important. This may include patient-reported
outcome measures and the assessment of health-related quality of
life in patients undergoing cardiac pacemaker implantation. While no
patient-reported outcome measures were selected in the final set of
QIs, the Working Group envisages that there is a need to develop
and validate patient-reported measures which are specific to the im-
plant of cardiac pacemakers.
The methodology used for the development of these QIs has limi-
tations. We relied on expert opinion to arrive at the final set of QIs.
Different panel of experts may have selected a different set of QIs,
but the use of the modified Delphi method to obtain group opinion,
and the involvement of patients and registry experts have provided
wide perspective and standardization to the selection process.
Furthermore, the application of a structured criteria, namely the ESC
criteria for QI development, in selecting the QIs and guiding the vot-
ing process improved the objectivity in building consensus amongst
the Working Group members.
Another limitation is the numerical thresholds used for the inclu-
sion of the QIs, and the selection between main and secondary ones.
Notwithstanding that these thresholds have been validated,22 and
recommended by the ESC methodology,16 one may anticipate that
different cut-offs may have retrieved different indicators. However,
having a structured method to interpret the experts’ opinion pro-
vided standardization to the process and consistency across the vari-
ous voting rounds. Given the number of the Working Group
members and the narrow scale of the voting, the accepted level of
inter-rater variation may be perceived too inclusive. However, this
approach was adopted to reduce the likelihood of excluding impor-
tant QIs which may be relevant to practice.
The developed QIs are intended to drive comprehensive patient
assessments and drive quality improvement, and, thus, should not be
considered in isolation. Furthermore, regular updates are needed for
these QIs and/or to their specifications when ‘real-world’ and feasibil-
ity data become available. It is hoped that the developed set of QIs
would be implemented in, and facilitate the development of, data col-
lection efforts aiming to assess and improve the quality of cardiac pac-
ing care. For instance, the European Unified Registries on Heart care
Evaluation and Randomized Trials (EuroHeart) project33 may favour
the implementation of methodologically developed QIs for future
cardiac device registries in Europe, which this statement uniquely
provides.
Conclusion
Using the ESC methodology for QI development, a set of QIs for car-
diac pacing have been developed across four key domains of care.
These QIs provide the means to systematically measure the quality
of care for patients undergoing cardiac pacemakers and capture care
outcomes through their implementation in daily practice and clinical
registries.
Supplementary material
Supplementary material is available at Europace online.
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